Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07840326
PHASE2

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

Sponsor: Sundance Biosciences, Inc.

View on ClinicalTrials.gov

Summary

The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.

Official title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2026-10

Completion Date

2027-07

Last Updated

2026-09-25

Healthy Volunteers

No

Interventions

DRUG

SUN-627

SUN-627, a once daily, orally administered, immediate release tablet

OTHER

Placebo

Orally-administered matched placebo

Locations (3)

Local Institution - Site 102

Atlanta, Georgia, United States

Local Institution - Site 101

Raleigh, North Carolina, United States

Local Institution - Site 104

Columbus, Ohio, United States